Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications?

M. H. Trivedi, J. Rush

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

During the last decade, there has been an increasing use of a placebo run-in period prior to randomization to active treatments, or placebo in randomized controlled trials aimed at establishing acute phase antidepressant drug efficacy in patients with major depression. This procedure is thought to reduce response rates to placebo treatment after randomization, thereby increasing the drug-placebo difference. Metaanalyses of 101 studies reveal that a placebo run-in does not (1) lower the placebo response rate, (2) increase the drug-placebo difference, or (3) affect the drug response rate post-randomization in either inpatients or outpatients for any antidepressant drug group. If there is a post-randomization placebo treatment cell, drug response rates are unchanged or are slightly lower than if there is no placebo treatment for outpatients. These results suggest that a pill placebo run-in provides no advantage in acute phase efficacy trials.

Original languageEnglish (US)
Pages (from-to)33-43
Number of pages11
JournalNeuropsychopharmacology
Volume11
Issue number1
StatePublished - 1994

Fingerprint

Antidepressive Agents
Placebos
Random Allocation
Therapeutics
Pharmaceutical Preparations
Outpatients
Inpatients
Randomized Controlled Trials

Keywords

  • Antidepressant medication
  • Depression
  • Metaanalysis
  • Placebo
  • Placebo run-in

ASJC Scopus subject areas

  • Pharmacology

Cite this

Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications? / Trivedi, M. H.; Rush, J.

In: Neuropsychopharmacology, Vol. 11, No. 1, 1994, p. 33-43.

Research output: Contribution to journalArticle

@article{99b43610ebd746fe971487df7c3d6d65,
title = "Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications?",
abstract = "During the last decade, there has been an increasing use of a placebo run-in period prior to randomization to active treatments, or placebo in randomized controlled trials aimed at establishing acute phase antidepressant drug efficacy in patients with major depression. This procedure is thought to reduce response rates to placebo treatment after randomization, thereby increasing the drug-placebo difference. Metaanalyses of 101 studies reveal that a placebo run-in does not (1) lower the placebo response rate, (2) increase the drug-placebo difference, or (3) affect the drug response rate post-randomization in either inpatients or outpatients for any antidepressant drug group. If there is a post-randomization placebo treatment cell, drug response rates are unchanged or are slightly lower than if there is no placebo treatment for outpatients. These results suggest that a pill placebo run-in provides no advantage in acute phase efficacy trials.",
keywords = "Antidepressant medication, Depression, Metaanalysis, Placebo, Placebo run-in",
author = "Trivedi, {M. H.} and J. Rush",
year = "1994",
language = "English (US)",
volume = "11",
pages = "33--43",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications?

AU - Trivedi, M. H.

AU - Rush, J.

PY - 1994

Y1 - 1994

N2 - During the last decade, there has been an increasing use of a placebo run-in period prior to randomization to active treatments, or placebo in randomized controlled trials aimed at establishing acute phase antidepressant drug efficacy in patients with major depression. This procedure is thought to reduce response rates to placebo treatment after randomization, thereby increasing the drug-placebo difference. Metaanalyses of 101 studies reveal that a placebo run-in does not (1) lower the placebo response rate, (2) increase the drug-placebo difference, or (3) affect the drug response rate post-randomization in either inpatients or outpatients for any antidepressant drug group. If there is a post-randomization placebo treatment cell, drug response rates are unchanged or are slightly lower than if there is no placebo treatment for outpatients. These results suggest that a pill placebo run-in provides no advantage in acute phase efficacy trials.

AB - During the last decade, there has been an increasing use of a placebo run-in period prior to randomization to active treatments, or placebo in randomized controlled trials aimed at establishing acute phase antidepressant drug efficacy in patients with major depression. This procedure is thought to reduce response rates to placebo treatment after randomization, thereby increasing the drug-placebo difference. Metaanalyses of 101 studies reveal that a placebo run-in does not (1) lower the placebo response rate, (2) increase the drug-placebo difference, or (3) affect the drug response rate post-randomization in either inpatients or outpatients for any antidepressant drug group. If there is a post-randomization placebo treatment cell, drug response rates are unchanged or are slightly lower than if there is no placebo treatment for outpatients. These results suggest that a pill placebo run-in provides no advantage in acute phase efficacy trials.

KW - Antidepressant medication

KW - Depression

KW - Metaanalysis

KW - Placebo

KW - Placebo run-in

UR - http://www.scopus.com/inward/record.url?scp=0027933111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027933111&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 33

EP - 43

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 1

ER -